Report Content
Chapter 1 Methodology
1.1 Market definitions
1.2 Base estimates & working
1.3 Forecast calculations
1.4 Data validation
1.5 Data sources
1.5.1 Secondary
1.5.1.1 Paid sources
1.5.1.2 Unpaid sources
1.5.2 Primary
Chapter 2 Executive Summary
2.1 Rapid influenza diagnostic tests industry 3600 synopsis, 2017 - 2030
2.1.1 Business trends
2.1.2 End-use trends
2.1.3 Regional Trends
Chapter 3 Rapid Influenza Diagnostic Tests Industry Insights
3.1 Industry segmentation
3.2 Industry landscape, 2017 – 2030 (USD Million)
3.3 Industry impact forces
3.3.1 Growth drivers
3.3.1.1 Growing prevalence of influenza
3.3.1.2 Technological advancements
3.3.1.3 Rising demand for early diagnosis and control of influenza
3.3.1.4 Increasing popularity of rapid diagnostic tests
3.3.1.5 Diagnostic advantages in influenza testing
3.3.2 Industry pitfalls & challenges
3.3.2.1 Lack of skilled professionals
3.3.2.2 Stringent regulations
3.4 Growth potential analysis
3.4.1 By end-use
3.5 COVID-19 impact analysis
3.6 Porter’s analysis
3.7 Competitive landscape, 2021
3.7.1 Company matrix analysis, 2021
3.8 PESTEL analysis
Chapter 4 Rapid Influenza Diagnostic Tests Market, By End-use
4.1 Key segment trends
4.2 Hospitals
4.2.1 Market size, by region, 2017 - 2030 (USD Million)
4.3 Diagnostics centers,
4.3.1 Market size, by region, 2017 - 2030 (USD Million)
4.4 Research laboratories
4.4.1 Market size, by region, 2017 - 2030 (USD Million)
4.5 Others
4.5.1 Market size, by region, 2017 - 2030 (USD Million)
Chapter 5 Rapid Influenza Diagnostic Tests Market, By Region
5.1 Key regional trends
5.2 North America
5.2.1 Market size, by country, 2017 - 2030 (USD Million)
5.2.2 Market size, by end-use, 2017 - 2030 (USD Million)
5.2.3 U.S.
5.2.3.1 Market size, by end-use, 2017 - 2030 (USD Million)
5.2.4 Canada
5.2.4.1 Market size, by end-use, 2017 - 2030 (USD Million)
5.3 Europe
5.3.1 Market size, by country, 2017 - 2030 (USD Million)
5.3.2 Market size, by end-use, 2017 - 2030 (USD Million)
5.3.3 Germany
5.3.3.1 Market size, by end-use, 2017 - 2030 (USD Million)
5.3.4 UK
5.3.4.1 Market size, by end-use, 2017 - 2030 (USD Million)
5.3.5 France
5.3.5.1 Market size, by end-use, 2017 - 2030 (USD Million)
5.3.6 Italy
5.3.6.1 Market size, by end-use, 2017 - 2030 (USD Million)
5.3.7 Spain
5.3.7.1 Market size, by end-use, 2017 - 2030 (USD Million)
5.4 Asia Pacific
5.4.1 Market size, by country, 2017 - 2030 (USD Million)
5.4.2 Market size, by end-use, 2017 - 2030 (USD Million)
5.4.3 China
5.4.3.1 Market size, by end-use, 2017 - 2030 (USD Million)
5.4.4 Japan
5.4.4.1 Market size, by end-use, 2017 - 2030 (USD Million)
5.4.5 India
5.4.5.1 Market size, by end-use, 2017 - 2030 (USD Million)
5.4.6 Australia
5.4.6.1 Market size, by end-use, 2017 - 2030 (USD Million)
5.4.7 South Korea
5.4.7.1 Market size, by end-use, 2017 - 2030 (USD Million)
5.5 Latin America
5.5.1 Market size, by country, 2017 - 2030 (USD Million)
5.5.2 Market size, by end-use, 2017 - 2030 (USD Million)
5.5.3 Brazil
5.5.3.1 Market size, by end-use, 2017 - 2030 (USD Million)
5.5.4 Mexico
5.5.4.1 Market size, by end-use, 2017 - 2030 (USD Million)
5.5.5 Argentina
5.5.5.1 Market size, by end-use, 2017 - 2030 (USD Million)
5.6 Middle East & Africa
5.6.1 Market size, by country, 2017 - 2030 (USD Million)
5.6.2 Market size, by end-use, 2017 - 2030 (USD Million)
5.6.3 South Africa
5.6.3.1 Market size, by end-use, 2017 - 2030 (USD Million)
5.6.4 Saudi Arabia
5.6.4.1 Market size, by end-use, 2017 - 2030 (USD Million)
5.6.5 UAE
5.6.5.1 Market size, by end-use, 2017 - 2030 (USD Million)
Chapter 6 Company Profiles
6.1 Competitive dashboard, 2021
6.2 F. Hoffmann-La Roche Ltd
6.2.1 Business overview
6.2.2 Financial data
6.2.3 Product landscape
6.2.4 Strategic outlook
6.2.5 SWOT analysis
6.3 Abbott
6.3.1 Business overview
6.3.2 Financial data
6.3.3 Product landscape
6.3.4 Strategic outlook
6.3.5 SWOT analysis
6.4 Becton, Dickinson and Company
6.4.1 Business overview
6.4.2 Financial data
6.4.3 Product landscape
6.4.4 Strategic outlook
6.4.5 SWOT analysis
6.5 Coris BioConcept
6.5.1 Business overview
6.5.2 Financial data
6.5.3 Product landscape
6.5.4 Strategic outlook
6.5.5 SWOT analysis
6.6 DiaSorin SpA
6.6.1 Business overview
6.6.2 Financial data
6.6.3 Product landscape
6.6.4 Strategic outlook
6.6.5 SWOT analysis
6.7 Meridian Bioscience Inc.
6.7.1 Business overview
6.7.2 Financial data
6.7.3 Product landscape
6.7.4 Strategic outlook
6.7.5 SWOT analysis
6.8 Quidel Corporation
6.8.1 Business overview
6.8.2 Financial data
6.8.3 Product landscape
6.8.4 Strategic outlook
6.8.5 SWOT analysis
6.9 Sekisui Diagnostics
6.9.1 Business overview
6.9.2 Financial data
6.9.3 Product landscape
6.9.4 Strategic outlook
6.9.5 SWOT analysis
6.10 Thermo Fischer Scientific Inc.
6.10.1 Business overview
6.10.2 Financial data
6.10.3 Product landscape
6.10.4 Strategic outlook
6.10.5 SWOT analysis
6.11 Hologic Inc.
6.11.1 Business overview
6.11.2 Financial data
6.11.3 Product landscape
6.11.4 Strategic outlook
6.11.5 SWOT analysis
